Navigation Links
Tokai Pharmaceuticals' galeterone well-tolerated in patients with advanced prostate cancer
Date:3/31/2012

CAMBRIDGE, Mass. and CHICAGO, Ill. -- Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study. The data will be presented in an oral presentation titled, "ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy nave patients with castration-resistant prostate cancer (CRPC)," abstract number CT-07, on Tuesday, April 3, 2012 at 3:05 p.m. (CDT) at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago.

CRPC is an advanced, difficult-to-treat form of prostate cancer that occurs when the disease progresses despite the use of anti-hormonal therapies. Galeterone is a small molecule, oral drug for the treatment of CRPC that disrupts the growth and survival of prostate cancer cells via a novel and proprietary triple mechanism of action.

"Because currently available therapeutic options to treat castration-resistant prostate cancer are limited, often poorly-tolerated and may fail because of resistance, patients are in urgent need of new safe and effective treatments," said Mary-Ellen Taplin, M.D., associate professor of medicine, director of genitourinary clinical research, Dana-Farber Cancer Institute, Harvard Medical School and co-lead researcher in the study. "These Phase 1 galeterone data, demonstrating minimal toxicities, improved PSA response and a reduction in tumor size, are exciting for those of us in the medical community treating this life-threatening cancer. I look forward to following the further development of galeterone as a promising approach in the treatment of prostate cancer."

The ARMOR1 study was led by co-principal investigators Dr. Taplin and Bruce Montgomery, M.D., associate professor of medical oncolo
'/>"/>

Contact: Caton Lovett
caton@purecommunicationsinc.com
910-232-7166
Pure Communications Inc.
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
2. 2012 Biotechnology and Pharmaceuticals: Forthcoming Conferences and Exhibitions
3. Study finds an increase of children accidentally poisoned with pharmaceuticals
4. Study Shows Sutro Biopharmas Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals
5. PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. Enter into a Licensing and Collaboration Agreement on PEP02 (MM-398), Nanoliposomal Irinotecan
6. Environmental risk assessment of pharmaceuticals inadequate
7. Brown licenses potential muscular dystrophy treatment to Tivorsan Pharmaceuticals
8. CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
9. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
10. NIH awards $8.5 million for research on pharmaceuticals for children
11. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... July 27, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Huawei has selected the ... for its stylish smartwatch. Huawei chose the state-of-the-art ... low power and highly responsive human interface qualities ... designers also required a classic round watch face ...
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/13/2015)... July 13, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced sampling of ClearPad ® ... driver integration (TDDI) product targeting smartphones and tablets. ... combine Synaptics , best-in-class touch controller IP ... technology developed in the company,s Japan Design Center. ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... In a discovery that seems counterintuitive, a study appearing ... has found that tendons in high-stress and strain ... frequently than low-stress tendons. This study sheds some light ... during aging. Tendons, composed of collagen and other ...
... a defect in cellular pathways that provides a new explanation ... known as craniosynostosis. Mutations of the WNT and ... regulate bone formation at the stem cell level, according to ... Science Signaling . "Our work contributes to the overall ...
... Rensselaer Polytechnic Institute and principal investigator Glenn Monastersky have been ... Stem Cell Science Program (NYSTEM) of the Empire State Stem ... the Center for Biotechnology and Interdisciplinary Studies (CBIS), said the ... excellence for basic stem cell research within the CBIS. ...
Cached Biology News:High-strain tendons repair less frequently 2Stem-cell disruption induces skull deformity, UR study shows 2Rensselaer Polytechnic Institute wins $2.45 million grant to support stem cell research 2
(Date:8/4/2015)... ANGELES , Aug. 4, 2015   California ... the recent acquisition of LifeLine Cryogenics, an east coast ... New York tristate area. LifeLine ... and all prepaid contracts will be honored. ... cryogenics services, offering storage of sperm, eggs, embryos, and ...
(Date:8/3/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... Annual Canaccord|Genuity Growth Conference in Boston, ... CEO, William C. Taylor , President and COO, ...
(Date:8/3/2015)... Delaware , August 3, 2015 ... in the commercialization of its Bio-electrical Signal Therapy device ... noninvasive treatment of hard to heal chronic wounds, today ... agreement with Chemipal, an Israeli distributor specializing in medical ... device. Chemipal is a 70 years old, ...
(Date:7/31/2015)... July 31, 2015 In today,s fast ... help them drive positive health outcomes, improve profitability ... of patient care in their communities. At ThoughtSpot ... and conference, AmerisourceBergen announced a new set of ... Administration Organization and help independent pharmacies endure the ...
Breaking Biology Technology:FamilyCord Announces Acquisition of LifeLine Cryogenics 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3
... Advanced Instruments, Inc . today introduced the ... automation-friendly osmometer for the biopharmaceutical industry."The ... designed for -- and completely redefines -- automation ... said Kelly Peterson, Product Manager, Advanced Instruments ( ...
... announced today,promising findings on the in vitro ... cancer developed on the basis of its ... both in vitro and in vivo models,Santaris ... inhibition of disease-associated microRNAs due to their ...
... April 20 Psylin Neurosciences Inc., ... Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. announced today ... novel compound, PSN0041, for the treatment of depression.(Logo: ... )PSN0041, a peptide from Amylin,s proprietary polypeptide hormone ...
Cached Biology Technology:Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 2Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 3LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs 2Psylin Neurosciences Commences Development of Compound for Depression 2Psylin Neurosciences Commences Development of Compound for Depression 3
Contains L-glutamine...
... the 11(R)-LOs of the sea urchin, ... hydra, H. vulgaris. The biological activity ... and tentacle regeneration, respectively, in these ... aspirin-treated recombinant COX-2 is incubated with ...
Rabbit anti-T-box 6...
karyopherin alpha2 (2G7)...
Biology Products: